Trusted Resources: Education
Scientific literature and patient education texts
Ethical Perspectives on Treatment Options With Spinal Muscular Atrophy Patients
source: Annals of neurology
year: 2022
authors: Yeo CJJ,Simmons Z,De Vivo DC,Darras BT
summary/abstract:Since 2016, three innovative therapies for spinal muscular atrophy have changed the face of disease. Although these therapies often result in remarkable improvements in infants and children, benefits in adults are modest and treatment is not curative. Concerns have been raised about the enormous costs of these medications, the ultimate burden to taxpayers, and the costs to society of withholding treatments and sacrificing or disadvantaging some individuals. Physicians are best positioned to serve our patients by carefully considering the costs, benefits, implications for quality of life, and the interplay of these factors within the framework of core ethical principles that guide clinical care. This article is protected by copyright. All rights reserved.
organization: Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.DOI: 10.1002/ana.26299
read more
Related Content
-
Comparison of Nusinersen and Evrysdi in the Treatment of Spinal Muscular AtrophySpinal Muscular Atrophy (SMA) is a genet...
-
Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated With NusinersenObjective: To retrospectively evaluate t...
-
Nusinersen: A Review in 5q Spinal Muscular AtrophySurvival motor neuron 1 (SMN1), located ...
-
Pediatric Spinal Muscular AtrophyWhat is spinal muscular atrophy (SMA)?Sp...
-
Despite Taking Spinraza, SMA Type 1 Children Show Nonmotor ProblemsDespite its well-reported benefits in mo...
-
The Antisense Oligonucleotide Nusinersen for Treatment of Spinal Muscular AtrophySpinal muscular atrophy (SMA) is a rare,...
-
Lunch & Learn: Gene Therapy for SMAhttps://www.youtube.com/watch?v=YFEMR1ZH...